Mpox-HIV Coinfection Increases Hospitalization Risk in Immunosuppressed Patients

The recent global outbreak of mpox (formerly monkeypox) brought to light significant concerns regarding its impact on individuals living with Human Immunodeficiency Virus (HIV). A core claim, extensively verified by real-time information, is that mpox-HIV coinfection is tied to a higher risk of hospitalization and more severe clinical outcomes. This association is particularly pronounced in people with uncontrolled HIV infection or those experiencing immunosuppression, characterized by low CD4+ T-cell counts. Multiple credible sources, including systematic reviews and meta-analyses, corroborate this finding. A meta-analysis published in March 2024 provided substantial evidence that HIV and mpox coinfection negatively impacts clinical outcomes, with co-infected individuals facing higher hospitalization and significantly higher mortality rates. This study, encompassing 21 articles and over 35,000 participants, found that people with both HIV and mpox had a higher hospitalization rate (odds ratio [OR] 1.848) and markedly higher mortality rates (OR 3.887) compared to those without HIV coinfection. The European Medical Journal itself reported in July 2023 that while patients with well-controlled HIV and mpox infection did not experience an increased risk of hospitalization, uncontrolled HIV and immunosuppression significantly elevated this risk. Immunosuppression, a hallmark of advanced or uncontrolled HIV, is identified as a critical factor. HIV compromises the body's immune response, making it more challenging to fight off other pathogens like the mpox virus. Studies consistently show that individuals with low CD4 counts (e.g., below 350 or 200 cells/µL) or unsuppressed viral loads are at a greater risk for severe mpox, including disseminated infection, larger and more necrotic lesions, and a prolonged disease course. For instance, the CDC highlights that people with advanced HIV who are immunocompromised are at increased risk of severe illness and death from mpox. Clinical manifestations in co-infected individuals often present with increased severity. A retrospective analysis from Hangzhou, China, examining 104 mpox cases among men who have sex with men (MSM), found that mpox-HIV coinfection was associated with a greater symptom burden, including more frequent lesion pain. Crucially, all 27 hospitalizations in this cohort, including one intensive care admission, occurred in the co-infected group. Other reports indicate more severe or atypical presentations, such as extensive anogenital lesions, proctitis requiring hospitalization, secondary bacterial infections, and in severe cases, multi-organ involvement or a 'fulminant mpox' form with massive, necrotizing lesions, especially in those with very low CD4 counts. The news is globally relevant. Mpox outbreaks have affected over 100 countries, with a significant proportion of cases, often between 30-60%, occurring in people living with HIV. Studies have been conducted across various regions, including Europe, North America, Brazil, Nigeria, and China, contributing to a global understanding of this co-infection. The disproportionate impact on MSM populations further emphasizes the need for targeted public health interventions. Effective management strategies are crucial. The World Health Organization (WHO) strongly recommends rapid initiation of antiretroviral therapy (ART) in people living with HIV who are diagnosed with mpox to reduce mortality and achieve viral suppression. Maintaining an undetectable viral load through consistent ART is considered one of the best ways for people with HIV to stay healthy and prevent severe illness if exposed to mpox. Mpox vaccines (like JYNNEOS) are safe and effective for people living with HIV, regardless of CD4 count, and are recommended for prevention, particularly for those with potential exposure. Additionally, early HIV testing for all individuals presenting with suspected or confirmed mpox is vital, as mpox diagnosis can serve as an opportunity for HIV screening. The headline "Mpox-HIV Coinfection Tied to Higher Hospitalization" accurately reflects the general consensus, though the nuance of 'uncontrolled HIV' and 'immunosuppression' is a crucial detail for complete accuracy, which the broader scientific literature and even the European Medical Journal's own coverage confirms. There is no evidence of misinformation or sensationalism, but rather a concise headline that accurately points to a significant medical finding. The data is current, with some key publications and updates occurring in late 2025 and early 2026. In conclusion, the verifiable evidence strongly supports the increased risk of severe mpox and hospitalization in individuals co-infected with HIV, especially when HIV is not well-managed or has led to significant immunosuppression. This underscores the importance of integrated public health approaches, rapid diagnosis, optimized HIV treatment, and targeted vaccination efforts to mitigate the impact of mpox in this vulnerable population worldwide.

Frequently Asked Questions

Read Full Story on Quick Digest